

Verastem, Inc. (VSTM)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001526119

Verastem, Inc.

VSTM; healthcare

Grade

B

A

B

C

D

E

second fifth of 371 graded peers

percentile 31.4; sampling error 2.5 points; lower is stronger

Rank

117 of 371

Profitability

A

percentile 10.4

Solvency

D

percentile 71.3

Growth and financing

C

percentile 45.9

Reliability

0.87 AUC

filers with \$120M to \$591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025

Peer failure rate

1.03% a year

Item 1.03 bankruptcies, same asset band, 2012 to 2025

Size band

\$120M to \$591M assets

total assets \$246.4M

Standard universe

inside

revenue above \$1M and assets above \$10M

Warnings

dilution; fortress balance sheet

Inputs computable

7 of 14

Graded from

filings received through Mar 4, 2026

219 days before the rescan; latest periodic filing 10-Q received Aug 6, 2026

Last close

\$8.11

2026-10-08; market equity \$734.5M

Price used in grade

None



B, the elk

second fifth of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescan

split-adjusted close; the letter is fixed at the rescan that set it



Rescans on file: D from Apr 21, 2022, E from Mar 21, 2023, B from Aug 21, 2026

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Mar 4, 2026

We are a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with challenging RAS/MAPK pathway-driven cancers. We market AVMAPKI FAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets) in the United States ("U.S."), the first treatment specifically FDA-approved for adults with KRAS-mutated recurrent low-grade serous ovarian cancer ("LGSOC") who have received prior systemic therapy. AVMAPKI FAKZYNJA CO-PACK received accelerated approval in the U.S. on May 8, 2025.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 10.4						
Gross profitability		not computable	32.2%			latest aligned inputs end 2018-12-31; latest annual assets end 2025-12-31
Return on invested capital		not computable	9.3%			pretax income must exceed the validity floor and imply a 0%-100% tax rate
Accruals ratio		(41.4%)	(6.6%)	10.4	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 1
Solvency, sleeve percentile 71.3						
Twelve-month failure probability		0.14%	0.07%	64.8	248	2026-06-30
Altman Z double-prime		(15.71)	(0.31)	70.3	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			EBITDA must exceed \$100,000
Interest coverage		(149.50x)	(4.51x)	95.0	81	2025-12-31
Current ratio		3.09x	2.96x	55.1	839	2025-12-31
Growth and financing, sleeve percentile 45.9						
Revenue growth, three-year compound		not computable	10.0%			four consecutive annual observations are required
Free cash flow growth, three-year compound		not computable	10.9%			four consecutive annual FCF observations are required; found 10
Reinvestment rate		not computable	37.1%			pretax income must exceed the validity floor and imply a 0%-100% tax rate
Asset growth, three years		37.4%	2.1%	11.9	704	2025-12-31
Net share issuance, one year		70.6%	2.5%	79.9	634	2026-02-27

Warnings


2 of 7 checks triggered; none of them enters the letter

Check	Measured
-------	----------

Dilution	split-adjusted year-over-year share growth is 70.6%
Fortress balance sheet	cash minus debt is 48,094,000 USD; Altman Z is not used

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
112	Cadre Holdings, Inc. (CDRE)	30.0	B	
113	MSA Safety Inc. (MSA)	30.3	B	
114	BioNexus Gene Lab Corp. (BGLC)	30.5	B	dilution, late filer
115	Arcutis Biotherapeutics, Inc. (ARQT)	30.8	B	
116	Bio-Techne Corp. (TECH)	31.1	B	fortress balance sheet
117	Verastem, Inc. (VSTM) <	31.4	B	dilution, fortress balance sheet
118	Stryker Corp. (SYK)	31.6	B	
119	Usana Health Sciences Inc. (USNA)	31.9	B	
120	Eton Pharmaceuticals, Inc. (ETON)	32.2	B	
121	CVRx, Inc. (CVRX)	32.4	B	
122	Koru Medical Systems, Inc. (KRMD)	32.7	B	fortress balance sheet

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(18.2%)	8.0%	31
Distance from 52-week high	(23.8%)	(31.4%)	61
EBIT to enterprise value	(26.6%)	(1.5%)	20
Free cash flow yield	(14.3%)	(1.0%)	27
Book value to price	0.07	0.28	22
Sales to price	0.04	0.31	15
Composite equity issuance, five years	184.5%	20.3%	87
Relative strength against the sector, log excess return	(0.41)	(0.14)	31

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass

No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$136.4M
Operating cash flow, four quarters	-\$162.2M
Months of runway	10.1
Days since last periodic filing	64 (10-Q received Aug 6, 2026)
Median daily dollar volume, 63 sessions	\$14.0M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$26.7M	2018-12-31	2021-03-18	10-K	0001558370-21-003211
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$165,000	2018-12-31	2019-03-12	10-K	0001558370-19-001852
3	assets	us-gaap:Assets	\$277.2M	2018-12-31	2020-03-11	10-K	0001558370-20-002421
4	operating income	us-gaap:OperatingIncomeLoss	-\$115.0M	2024-12-31	2026-03-04	10-K	0001104659-26-023444
5	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDeductibleItemsAndNoncontrollingInterests	\$180.5M	2024-12-31	2026-03-04	10-K	0001104659-26-023444
6	income tax	us-gaap:IncomeTaxExpenseBenefit	\$185,000	2024-12-31	2026-03-04	10-K	0001104659-26-023444
7	total debt	us-gaap:LongTermDebt	\$40.7M	2024-12-31	2026-03-04	10-K	0001104659-26-023444
8	book equity	us-gaap:StockholdersEquity	-\$28.9M	2024-12-31	2026-03-04	10-K	0001104659-26-023444
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$88.8M	2024-12-31	2026-03-04	10-K	0001104659-26-023444
10	total debt	us-gaap:LongTermDebt	\$40.1M	2023-12-31	2025-03-20	10-K	0001558370-25-003372
11	book equity	us-gaap:StockholdersEquity	\$57.4M	2023-12-31	2026-03-04	10-K	0001104659-26-023444
12	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$77.9M	2023-12-31	2025-03-20	10-K	0001558370-25-003372
13	net income	us-gaap:NetIncomeLoss	-\$209.5M	2025-12-31	2026-03-04	10-K	0001104659-26-023444
14	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$137.5M	2025-12-31	2026-03-04	10-K	0001104659-26-023444
15	assets	us-gaap:Assets	\$246.4M	2025-12-31	2026-03-04	10-K	0001104659-26-023444
16	assets	us-gaap:Assets	\$101.5M	2024-12-31	2026-03-04	10-K	0001104659-26-023444
17	current assets	us-gaap:AssetsCurrent	\$223.4M	2025-12-31	2026-03-04	10-K	0001104659-26-023444
18	current liabilities	us-gaap:LiabilitiesCurrent	\$72.3M	2025-12-31	2026-03-04	10-K	0001104659-26-023444
19	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$1.2B	2025-12-31	2026-03-04	10-K	0001104659-26-023444
20	operating income	us-gaap:OperatingIncomeLoss	-\$170.1M	2025-12-31	2026-03-04	10-K	0001104659-26-023444
21	book equity	us-gaap:StockholdersEquity	\$57.2M	2025-12-31	2026-03-04	10-K	0001104659-26-023444
22	liabilities	us-gaap:Liabilities	\$189.2M	2025-12-31	2026-03-04	10-K	0001104659-26-023444
23	depreciation amortization	us-gaap:Depreciation	\$26,000	2024-12-31	2026-03-04	10-K	0001104659-26-023444
24	interest expense	us-gaap:InterestExpense	\$1.1M	2025-12-31	2026-03-04	10-K	0001104659-26-023444
25	revenue	us-gaap:Revenues	\$30.9M	2025-12-31	2026-03-04	10-K	0001104659-26-023444
26	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$10.0M	2024-12-31	2025-03-20	10-K	0001558370-25-003372
27	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$2.6M	2022-12-31	2025-03-20	10-K	0001558370-25-003372
28	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$2.1M	2021-12-31	2023-03-14	10-K	0001558370-23-003738
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$28,000	2024-12-31	2026-03-04	10-K	0001104659-26-023444
30	current assets	us-gaap:AssetsCurrent	\$95.0M	2024-12-31	2026-03-04	10-K	0001104659-26-023444
31	current liabilities	us-gaap:LiabilitiesCurrent	\$31.0M	2024-12-31	2026-03-04	10-K	0001104659-26-023444
32	current assets	us-gaap:AssetsCurrent	\$143.7M	2023-12-31	2025-03-20	10-K	0001558370-25-003372
33	current liabilities	us-gaap:LiabilitiesCurrent	\$26.4M	2023-12-31	2025-03-20	10-K	0001558370-25-003372
34	assets	us-gaap:Assets	\$149.7M	2023-12-31	2025-03-20	10-K	0001558370-25-003372
35	assets	us-gaap:Assets	\$95.0M	2022-12-31	2024-03-14	10-K	0001558370-24-003250
36	shares outstanding	dei:EntityCommonStockSharesOutstanding	87,835,106	2026-02-27	2026-03-04	10-K	0001104659-26-023444
37	shares outstanding	dei:EntityCommonStockSharesOutstanding	51,486,705	2025-03-19	2025-03-20	10-K	0001558370-25-003372